These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30341231)

  • 61. Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients.
    Karim MR; Ahmed H; Paul RK; Chowdhury M; Alam MS; Saha A
    Mymensingh Med J; 2016 Apr; 25(2):198-204. PubMed ID: 27277347
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
    Mintziori G; Polyzos SA
    Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials.
    Wang H; Ma Q; Chen Y; Luo L; Ye J; Zhong B
    Obes Rev; 2024 Jun; 25(6):e13727. PubMed ID: 38509775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Pharmacological treatment of NASH].
    Serfaty L
    Presse Med; 2019 Dec; 48(12):1489-1495. PubMed ID: 31757735
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH.
    Rizzo M; Montalto G; Vinciguerra M
    Curr Vasc Pharmacol; 2014; 12(5):741-4. PubMed ID: 23305377
    [No Abstract]   [Full Text] [Related]  

  • 69. Low-carbohydrate diets and intrahepatic lipid content in individuals with non-alcoholic fatty liver disease: Evidence from a meta-analysis of randomized trials.
    Bueno NB; Dos Santos Silva MM; de Melo ISV
    Clin Nutr; 2020 Jan; 39(1):310-311. PubMed ID: 31791671
    [No Abstract]   [Full Text] [Related]  

  • 70. Elafibranor for the treatment of NAFLD: One pill, two molecular targets and multiple effects in a complex phenotype.
    Sookoian S; Pirola CJ
    Ann Hepatol; 2016; 15(4):604-9. PubMed ID: 27236162
    [No Abstract]   [Full Text] [Related]  

  • 71. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Non-alcoholic fatty liver disease - A global public health perspective.
    Younossi ZM
    J Hepatol; 2019 Mar; 70(3):531-544. PubMed ID: 30414863
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
    Ogawa Y; Yoneda M; Kobayashi T; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A
    Expert Opin Pharmacother; 2019 Jan; 20(1):69-82. PubMed ID: 30411635
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
    Wang B; Sun Y; Sang Y; Liu X; Liang J
    Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus.
    Perna S; Mainardi M; Astrone P; Gozzer C; Biava A; Bacchio R; Spadaccini D; Solerte SB; Rondanelli M
    Clin Pharmacol; 2018; 10():141-151. PubMed ID: 30349407
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
    Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
    J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
    Tacelli M; Celsa C; Magro B; Giannetti A; Pennisi G; Spatola F; Petta S
    Pharmaceuticals (Basel); 2018 Nov; 11(4):. PubMed ID: 30413050
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.